ERBB2 and breast carcinoma: In particular, miRNA expression profiling of human breast cancer subtypes, as classified by ER, progesterone receptor, and ErbB2/Her2 receptor statuses, has revealed miRNA signatures that not only correlate with the molecular subtype, but can also serve as potential prognostic markers and indicators of patient responses to facilitate personalized treatment approaches.